Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists

Clicks: 1
ID: 299342
2004
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #395 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The relationship between the use of tumor necrosis factor antagonists and onset of granulomatous infection was examined using data collected through the Adverse Event Reporting System of the US Food and Drug Administration for January 1998–September 2002. Granulomatous infections were reported at rates of ∼239 per 100,000 patients who received infliximab and ∼74 per 100,000 patients who received etanercept (P < .001). Tuberculosis was the most frequently reported disease, occurring in ∼144 and ∼35 per 100,000 infliximab-treated and etanercept-treated patients, respectively (P < .001). Candidiasis, coccidioidomycosis, histoplasmosis, listeriosis, nocardiosis, and infections due to nontuberculous mycobacteria were reported with significantly greater frequency among infliximab-treated patients. Seventy-two percent of these infection occurred ⩽90 days after starting infliximab treatment, and 28% occurred after starting etanercept treatment (P < .001). These data indicate a risk of granulomatous infection that was 3.25-fold greater among patients who received infliximab than among those who received etanercept. The clustering of reports shortly after initiation of treatment with infliximab is consistent with reactivation of latent infection.
Reference Key
openalex_W2114872119 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Robert S. Wallis, Michael S. Broder, Jia Yi Karen Wong, M. E. Hanson, David O. Beenhouwer
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2004
DOI
10.1086/383317
URL
https://academic.oup.com/cid/article-pdf/38/9/1261/901630/38-9-1261.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.